ClinicalTrials.gg
Active, not recruitingNCT05305365Updated Oct 20, 2026Results posted

Study Assessing QBS72S For Treating Brain Metastases

A Phase 2 interventional study of QBS72S in Brain Metastases, Breast Cancer and Lung Cancer, sponsored by Melanie Hayden Gephart. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Melanie Hayden Gephart · Phase 2, Interventional, and Treatment

How we know

Updated Oct 20, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,447 studies in Brain Neoplasms with a site in United States — 233 open to participants now, 355 under way, 18 of them phase 3. Brain Neoplasms · United States.

Enrollment
730th of 1,192
21 · median 30
Started
2022
with 58 others
Phase 2
383 of 1,447
50 open now
Primary completion
2025-06
later than 24 of 353 live
Registered
1,221st of 1,447
by date

Among the 1,447 studies in Brain Neoplasms with a site in United States, this one is the 730th largest by enrollment of the 1,192 interventional ones that give a count, is one of 59 that started in 2022, is one of 383 in phase 2, reaches primary completion later than 24 of the 353 other live ones, and was the 1,221st registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

233 of the 1,447 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:

228 more — sign in →

All 233 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,447 studies in Brain Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic cancer with CNS involvement

Read the detailed description

Primary Objective

1. Test of the preliminary efficacy of the intracranial anti tumor activity of QBS72S through overall response rate (ORR) in Cohort 1 (Stages 1+2).

Secondary Objectives

  1. Test of the preliminary efficacy of the intracranial anti tumor activity of QBS72S through progression free survival (PFS) in Cohort 1 (Stages 1+2).
  2. Test of the preliminary efficacy of the intracranial anti tumor activity of QBS72S through overall survival (OS) in Cohort 1 (Stages 1+2).
  3. Test of the preliminary efficacy of the intracranial anti tumor activity of QBS72S through durations of response (DoR) in Cohort 1 (Stages 1+2).
  4. Evaluate safety of QBS72S treatment in Cohort 1 (Stages 1+2), Cohort 2, and Cohort 3.
03

Conditions studied

  • Brain Metastases
  • Breast Cancer
  • Lung Cancer
  • Leptomeningeal Disease
  • LMD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant must be 18 years or older
  2. The participant must have a Performance Status (KPS) of 60 or above.
  3. One of the following:

    1. Cohorts 1 and 2: The participant must have a -confirmed breast cancer primary tumor, either confirmed via primary specimen or via site, having developed (parenchymal or LMD) after a prior cytotoxic chemotherapy regimen.
    2. Cohort 3: The participant must have a histologically cancerous primary tumor, either confirmed via primary specimen or via metastasis site, having developed brain metastases (parenchymal or LMD) after a prior cytotoxic chemotherapy regimen. There is no restriction on prior cycles of systemic therapy for any primary cancer type. Breast cancer is not excluded from Cohort 3.
  4. One of the following:

    1. Cohort 1: A participant with breast cancer brain parenchymal tumors must have at least one nonirradiated tumor ≥ 3 mm2 that can be seen on 2 or more separate acquired brain MRI sequences.
    2. Cohort 2: A participant with breast cancer primary and

    LMD must receive either:

    i. a brain MRI with contrast that supports the presence of LMD, or ii. a CSF cytology test that is either positive for or suspicious for . The presence of parenchymal brain metastases does not exclude these participants from Cohort 2.

    a. Cohort 3: A participant with LMD from any primary cancer site must receive either: i. a brain MRI with contrast that supports the presence of LMD, or ii. a CSF cytology test that is either positive for or suspicious for malignancy. The presence of parenchymal brain metastases does not exclude these participants from Cohort 3.

  5. For and anticonvulsants, the participant must either: c. not be taking any, or d. be taking stable or decreasing doses for ≥5 days prior to obtaining the screening Gd-MRI of the brain. The maximum allowable dose of corticosteroids is 8mg of dexamethasone per day, or the equivalent of another medication as assessed by a Neuro-Oncologist. Escalation of corticosteroids is not allowed ≤14 days prior to C1D1.
  6. The participant must have completed washout from prior therapy before C1D1, as applicable: e. ≥7 days for Ommaya placement (Cohorts 2+3) f. ≥14 days for small molecules and non-cytotoxic systemic drugs e.g., PARP inhibitors g. ≥21 days for and monoclonal antibodies, e.g., atezolizumab, pembrolizumab, and bevacizumab, and cytotoxic chemotherapy h. ≥28 days for drugs, radiotherapy, and major surgery. Minor procedures such as tumor are allowed with written approval from the PI i. ≥1 dosing cycle for other interventions All significant toxicities from previous anticancer therapy must have stabilized to a new baseline or have resolved. Participation in long term follow up in another clinical trial is allowed if no procedures will be performed which may interfere with the interpretation of study results.
  7. The participant must have adequate bone marrow function, including: j. ≥ 1,500/mm3 or ≥ 1.5 x 109/L k. ≥ 100,000/ mm3 or ≥ 100 x 109/L l. ≥ 9 g/dL
  8. The participant must have adequate renal function, including serum creatinine ≤ 1.5 x or estimated ≥ 50 mL/min. In equivocal cases, a 24-hour urine collection test can be used to estimate the creatinine clearance more accurately.
  9. The participant must have adequate liver function, including: m. Total serum ≤ 1.5 x ULN unless the participant has documented Gilbert syndrome who must have a total bilirubin \< 3.0 mg/dl n. Aspartate and (AST and ALT) ≤ 2.5 x ULN; ≤ 5.0 x ULN if there is liver involvement by the tumor
  10. Any participant physiologically capable of becoming pregnant or getting a partner pregnant must agree to use highly effective during study treatment and for 7 months after study discontinuation.
  11. Participants or their designated advocates must be willing to and capable of providing and willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures

Exclusion criteria

Exclusion Criteria

  1. Participants with any other current, active unrelated to their primary cancer diagnosis, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ.
  2. Participants with intolerance to or who have had a severe (Grade 3) allergic or anaphylactic reaction to any of the substances included in the product: sulfobutylether-β-cyclodextrin, melphalan, bendamustine, chlorambucil or any nitrogen mustard chemotherapeutics.
  3. Participants who currently use or have an anticipated need for a medication including , natalizumab, nivolumab, ocrelizumab, palifermin, pimecrolimus, tacrolimus, tofacitinib, and EIAEDs, including phenytoin, phenobarbital, carbamazepine, fosphenytoin, primidone, and oxcarbazepine. The for any live vaccine is 30 days prior to enrollment. There is no restriction for seasonal flu vaccines that do not contain live virus, nor any approved COVID vaccine.
  4. Participants who are pregnant or breastfeeding.
  5. Participants who have active medical or psychiatric conditions which, in the opinion of the Principal Investigator or a Sub-Investigator, would compromise or interfere with their ability to participate in the study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Patients with Breast Cancer Parenchymal brain metastasis (Cohort 1, Stage 1)

    All participants in Cohort 1 Stage 1 will receive QBS72S IV injections once monthly until disease progression.

    Drug: QBS72S

  • Experimental
    Patients with Breast Cancer Parenchymal brain metastasis (Cohort 1, Stage 2)

    All participants in Cohort 1 Stage 2 will receive QBS72S IV injections once monthly until disease progression. This cohort never opened to enrollment

    Drug: QBS72S

  • Experimental
    Patients with Breast Cancer Leptomeningeal Disease (Cohort 2)

    All participants in Cohort 3 will receive QBS72S IV injections once monthly until disease progression.

    Drug: QBS72S

  • Experimental
    Patients with any Primary Cancer Leptomeningeal Disease (Cohort 3)

    All participants in Cohort 3 will receive QBS72S IV injections once monthly until disease progression.

    Drug: QBS72S

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Against Intracranial Tumor Lesions, Cohort 1- Stage 1

    The overall response against the target intracranial tumor lesions in Cohort 1-Stage 1 participants was assessed by according to the modified Response Assessment in Neuro-oncology for Brain Metastases (mRANO-BM) and RECIST 1.1 response criteria. Clinical response means either a complete response (CR) or a partial response (CR). CR is defined as disappearance of tumor lesions, and PR is defined as ≥ 30% reduction in diameter of tumor lesions. The outcome is reported the number of Cohort 1- Stage 1 participants who achieved a CR or PR within 6 months from the start of treatment.

    Time frame: 6 months

Secondary outcomes

  1. Progression-free Survival (PFS), Cohort 1-Stage 1

    Progression-free Survival (PFS) means to remain alive without tumor progression, assessed as a ≥ 25% increase in tumor diameter. The outcome is reported as the number of participants in Cohort 1- Stage 1 who remained alive at 2 months without tumor progression.

    Time frame: 2 months

  2. Overall Survival (OS), Cohort 1- Stage 1

    Overall survival (OS) refers to remaining alive at the time of the assessment. The outcome is reported as the number of participants in Cohort 1- Stage 1 who remained alive at 2 months.

    Time frame: 2 months

  3. Duration of Response (DoR), Cohort 1 - Stage 1

    Duration of Response (DoR) referred to the length of time that a clinical response was maintained in Cohort 1 (Stages 1+2) participants. Clinical response means either a complete response (CR) or a partial response (PR). CR was defined as disappearance of tumor lesions, and PR was defined as ≥30% reduction in diameter of tumor lesions. The outcome was assessed at 6 months and reported as median DoR with standard deviation for Cohort 1-Stage 1 participants who achieved a clinical response. If no participants achieved a clinical response, DoR was not evaluable.

    Time frame: 6 months

  4. Related Adverse Events (AEs)

    Toxicity refers to drug-related adverse events (AEs). The outcome is reported as the number of related AEs that were serious per 21CFR§312.32 or non-serious, and by severity (mild, moderate, severe, life-threatening, or fatal), numbers without dispersion. Life-threatening events will only be those that are clinically life-threatening, and not merely a laboratory value without significant clinical symptoms.

    Time frame: 30 days following the last administration of study drug, up to 1 year

07

Results

Posted Oct 20, 2026

Participant flow

Participant flow — Overall Study
MilestonePatients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)Patients With Breast Cancer Leptomeningeal Disease (Cohort 2)Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3)
Started6105
Completed6105
Not completed000

Outcome measures

PrimaryOverall Response Against Intracranial Tumor Lesions, Cohort 1- Stage 1

The overall response against the target intracranial tumor lesions in Cohort 1-Stage 1 participants was assessed by according to the modified Response Assessment in Neuro-oncology for Brain Metastases (mRANO-BM) and RECIST 1.1 response criteria. Clinical response means either a complete response (CR) or a partial response (CR). CR is defined as disappearance of tumor lesions, and PR is defined as ≥ 30% reduction in diameter of tumor lesions. The outcome is reported the number of Cohort 1- Stage 1 participants who achieved a CR or PR within 6 months from the start of treatment.

Time frame:
6 months
Reported as:
Number · Participants
Overall Response Against Intracranial Tumor Lesions, Cohort 1- Stage 1
ParticipantsPatients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)
Complete Response (CR)0
Partial Response (CR)0
SecondaryProgression-free Survival (PFS), Cohort 1-Stage 1

Progression-free Survival (PFS) means to remain alive without tumor progression, assessed as a ≥ 25% increase in tumor diameter. The outcome is reported as the number of participants in Cohort 1- Stage 1 who remained alive at 2 months without tumor progression.

Time frame:
2 months
Reported as:
Number · Participants
Progression-free Survival (PFS), Cohort 1-Stage 1
ParticipantsPatients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)
Progression-free Survival (PFS), Cohort 1-Stage 10
SecondaryOverall Survival (OS), Cohort 1- Stage 1

Overall survival (OS) refers to remaining alive at the time of the assessment. The outcome is reported as the number of participants in Cohort 1- Stage 1 who remained alive at 2 months.

Time frame:
2 months
Reported as:
Number · Participants
Overall Survival (OS), Cohort 1- Stage 1
ParticipantsPatients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)
Overall Survival (OS), Cohort 1- Stage 11
SecondaryDuration of Response (DoR), Cohort 1 - Stage 1

Duration of Response (DoR) referred to the length of time that a clinical response was maintained in Cohort 1 (Stages 1+2) participants. Clinical response means either a complete response (CR) or a partial response (PR). CR was defined as disappearance of tumor lesions, and PR was defined as ≥30% reduction in diameter of tumor lesions. The outcome was assessed at 6 months and reported as median DoR with standard deviation for Cohort 1-Stage 1 participants who achieved a clinical response. If no participants achieved a clinical response, DoR was not evaluable.

Time frame:
6 months
Reported as:
Median · months
Duration of Response (DoR), Cohort 1 - Stage 1
monthsPatients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)
Duration of Response (DoR), Cohort 1 - Stage 10 ± 0
SecondaryRelated Adverse Events (AEs)

Toxicity refers to drug-related adverse events (AEs). The outcome is reported as the number of related AEs that were serious per 21CFR§312.32 or non-serious, and by severity (mild, moderate, severe, life-threatening, or fatal), numbers without dispersion. Life-threatening events will only be those that are clinically life-threatening, and not merely a laboratory value without significant clinical symptoms.

Time frame:
30 days following the last administration of study drug, up to 1 year
Reported as:
Number · Events
Related Adverse Events (AEs)
EventsPatients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)Patients With Breast Cancer Leptomeningeal Disease (Cohort 2)Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3)
Mild (Grade 1)32649
Moderate (Grade 2)9309
Severe (Grade 3)52411
Life-threatening (Grade 4)235
Fatal (Grade 5)000

Adverse events

Collected over 30 days following the last administration of study drug, up to 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)0/6 (0%)3/6 (50%)6/6 (100%)
Patients With Breast Cancer Leptomeningeal Disease (Cohort 2)0/10 (0%)5/10 (50%)10/10 (100%)
Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3)0/5 (0%)4/5 (80%)5/5 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPatients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)Patients With Breast Cancer Leptomeningeal Disease (Cohort 2)Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3)
SeizureNervous System Disorders0/62/102/5
NauseaGastrointestinal Disorders0/60/102/5
HeadacheNervous System Disorders0/60/102/5
DizzinessNervous System Disorders0/61/101/5
Edema, cerebralNervous system disorders0/62/100/5
HypoxiaRespiratory, Thoracic and Mediastinal Disorders1/61/101/5
ThrombocytopeniaBlood and lymphatic system disorders0/60/101/5
Lung infectionInfections and infestations0/60/101/5
ColitisGastrointestinal Disorders1/60/100/5
Back painMusculoskeletal and connective tissue disorders1/60/100/5
Most frequent other events
Showing 10 of 93
Most frequent other events
EventPatients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)Patients With Breast Cancer Leptomeningeal Disease (Cohort 2)Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3)
Lymphocyte count decreasedInvestigations5/66/101/5
White blood cell decreasedInvestigations5/67/102/5
Platelet count decreasedInvestigations4/67/101/5
NauseaGastrointestinal Disorders4/65/101/5
FallInjury, poisoning and procedural complications1/65/101/5
Absolute lymphocyte count decreasedInvestigations3/62/102/5
Absolute neutrophil count decreasedInvestigations3/65/100/5
VomitingGastrointestinal Disorders0/63/102/5
FatigueGeneral Disorders and Administration Site Conditions2/64/100/5
HyperuricemiaMetabolism and Nutrition Disorders0/60/102/5

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)Patients With Breast Cancer Leptomeningeal Disease (Cohort 2)Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3)Total
<=18 years0000
Between 18 and 65 years49518
>=65 years2103
Sex: Female, Male
Sex: Female, Male(Participants)Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)Patients With Breast Cancer Leptomeningeal Disease (Cohort 2)Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3)Total
Female610420
Male0011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)Patients With Breast Cancer Leptomeningeal Disease (Cohort 2)Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3)Total
Hispanic or Latino2002
Not Hispanic or Latino410519
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)Patients With Breast Cancer Leptomeningeal Disease (Cohort 2)Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3)Total
American Indian or Alaska Native0000
Asian1135
Native Hawaiian or Other Pacific Islander1001
Black or African American0000
White36110
More than one race0000
Unknown or Not Reported1315
Region of Enrollment
Region of Enrollment(participants)Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1)Patients With Breast Cancer Leptomeningeal Disease (Cohort 2)Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3)Total
United States610521
08

Study locations

1 site
09

References and documents

Publications

  • Nagpal S, Carlson-Clarke B, Rout SS, Trinh TTH, Roy-O'Reilly M, Tedjakusuma SN, Taiwo R, Harary PM, Granucci M, Chernikova SB, Bertrand S, Therkelsen KE, Han SS, Gu B, Bharani KL, Newman JM, Barisano G, Umeh-Garcia MC, Herrick D, Vogel H, Arora M, Samos CH, Soltys SG, Pollom EL, Rahimy E, Iv M, Melisko ME, Hayden Gephart M. Phase 2 test of QBS72S for breast cancer leptomeningeal disease. Neuro Oncol. 2026 Aug 7:noag177. doi: 10.1093/neuonc/noag177. Online ahead of print. PubMed 42565554 ↗
  • Taiwo R, Harary PM, Trinh TTH, Granucci M, Bertrand S, Carlson-Clarke B, Chernikova SB, Therkelsen K, Arora M, Melisko ME, Iv M, Vogel H, Han S, Xie C, Brain S, Lee V, Bharani KL, Nagpal S, Hayden Gephart M. Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases. BMC Cancer. 2025 Aug 15;25(1):1316. doi: 10.1186/s12885-025-14282-x. PubMed 40813655 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jun 2025, 34 months.

Results were first posted in Oct 2026, 1 year 4 months after primary completion.

Of 208 non-industry phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 100. This study's 34 months is below that.

Counting every sponsor, half of 252 studies reached it within 61 months; a quarter within 38 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2022
First posted
Mar 31, 2022
StartActual
Aug 16, 2022
Primary completionActual
Jun 20, 2025
CompletionEst.
Dec 2027
Results first posted
Oct 20, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 20, 2026
Interventions
Arm changed Patients with Breast Cancer Parenchymal brain metastasis (Cohort 1)→Patients with Breast Cancer Parenchymal brain metastasis (Cohort 1, Stage 1). Arms added: Patients with Breast Cancer Parenchymal brain metastasis (Cohort 1, Stage 2)
Oct 20, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedOverall Response againstAgainst Intracranial Tumor Lesions, Cohort 1 (Stages- Stage 1+2)Time frame: 6 months
  • RemovedRECIST 1.1 response criteriaTime frame: 6 months from the start of treatment
Oct 20, 2026
Documents
Secondary outcomes
3 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • EditedProgression-free Survival (PFS), Cohort 1 (Stages-Stage 1+2)Time frame: 2 months
  • EditedOverall Survival (OS), Cohort 1 (Stages- Stage 1+2)Time frame: 2 months
  • EditedDuration of Response (DoR), Cohort 1 (Stages- Stage 1+2)Time frame: 6 months
  • Time frameRelated Adverse Events (AEs)30 days following the last administration of study drug → 30 days following the last administration of study drug, up to 1 year
  • DescriptionRelated Adverse Events (AEs): how it is measured was reworded
Oct 20, 2026
Sponsor
Stanford University→Melanie Hayden Gephart
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Results posted
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedOverall Response againstAgainst Intracranial Tumor Lesions, Cohort 1 (Stages- Stage 1+2)Time frame: 6 months
    • RemovedRECIST 1.1 response criteriaTime frame: 6 months from the start of treatment
    Secondary outcomes 3 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • EditedProgression-free Survival (PFS), Cohort 1 (Stages-Stage 1+2)Time frame: 2 months
    • EditedOverall Survival (OS), Cohort 1 (Stages- Stage 1+2)Time frame: 2 months
    • EditedDuration of Response (DoR), Cohort 1 (Stages- Stage 1+2)Time frame: 6 months
    • Time frameRelated Adverse Events (AEs)30 days following the last administration of study drug → 30 days following the last administration of study drug, up to 1 year
    • DescriptionRelated Adverse Events (AEs): how it is measured was reworded
    Interventions Arm changed Patients with Breast Cancer Parenchymal brain metastasis (Cohort 1)→Patients with Breast Cancer Parenchymal brain metastasis (Cohort 1, Stage 1). Arms added: Patients with Breast Cancer Parenchymal brain metastasis (Cohort 1, Stage 2)
    Sponsor Stanford University→Melanie Hayden Gephart
    + 4 other changes: identifiers, verification date, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05305365
Lead sponsor
Melanie Hayden Gephart
Collaborators
Quadriga Biosciences, Inc.
Responsible party
Melanie Hayden Gephart (Professor of Neurosurgery, Stanford University) — Sponsor-investigator
First posted
Mar 31, 2022
Start date
Aug 16, 2022
Primary completion
Jun 20, 2025
Completion
Dec 2027 (estimated)
Results posted
Oct 20, 2026
Last update
Oct 20, 2026

Study contacts

Melanie H Gephart, MD, MAS
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytotoxic Agent-LAT1 Substrate QBS10072S

Start the discussion